Her-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3+CD56+ (natural killer T) lymphocytes

International Journal of Cancer

Volumn 98, Issue 6, 2002, Pages 864-872

  Baxevanis, Constantin N ^a   Gritzapis, Angelos D ^a   Tsitsilonis, Ourania E ^a   Katsoulas, Haralabos L ^a   Papamichail, Michael ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Cancer immunotherapy; Cytotoxicity; HER 2 neu peptides; Natural killer T cells; Ovarian cancer

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CELL EXTRACT; EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; NATURAL KILLER CELL; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD56; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MONOCYTES; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037140090     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10251     Document Type: Article

References (31)

1. Antigen presentation: Recent developments
2. Cells and cytokines in immunotherapy and gene therapy of cancer
3. Human tumor antigen for cancer vaccine development
4. HER-2/neu protein: A target for antigen-specific immunotherapy of human cancer
5. Human tumor antigens recognized by T cells
6. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
7. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
8. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
9. Human tumor antigens: Implications for cancer vaccine development
10. + killer cells
11. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
12. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia
13. + cells derived from T cells with potent in vivo anti-tumor activity in SCID mice
14. Generation and characterization of gp100 peptide-specific NK-T cell clones
15. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
16. Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
17. Identification of an immuno-dominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
18. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against pre-selected highly immunogenic melanoma cell clones
19. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer
20. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines
21. HER-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
22. + cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice
23. Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin α
24. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
25. The HER-2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
26. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
27. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers
28. ras peptide presented by HLA-A*0201
29. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
30. Analysis of TCR usage in human tumors: A new tool for assessing tumor-specific immune responses
31. In situ T cells in melanoma